Size : | Price | Quantity | |
---|---|---|---|
100 mg | $50.00 | ||
500 mg | $150.00 |
Apomorphine (41372-20-7) is an archetypal dopamine pan-receptor agonist. Displays anti-Parkinsons activity in vivo.1 Protects against MPTP-induced neurotoxicity in a mouse mode1,2 In clinical use for Parkinson’s disease.4,5
References/Citations:
1) Merck Index 14:746
2) Millan et al. (2002), Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes; J. Pharmacol. Exp. Therap., 303 791
3) Grunblatt et al. (1999), Apomorphine protects against MPTP-induced neurotoxicity in mice.; Mov. Discord, 14 612
4) Auffret et al. (2017), Apomorphine pump in advanced Parkinson’s disease: Effects on motor and nonmotor symptoms with brain metabolism correlations; J. Neurol. Sci, 372 279
5) Jenner and Katzenschlager (2016), Apomorphine – pharmacological properties and clinical trials in Parkinson’s disease; Parkinsonism. Related. Disord., 33 Suppl. 1:S13
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Apomorphine (41372-20-7) is an archetypal dopamine pan-receptor agonist. Displays anti-Parkinsons activity in vivo.1 Protects against MPTP-induced neurotoxicity in a mouse mode1,2 In clinical use for Parkinson’s disease.4,5
References/Citations:
1) Merck Index 14:746
2) Millan et al. (2002), Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes; J. Pharmacol. Exp. Therap., 303 791
3) Grunblatt et al. (1999), Apomorphine protects against MPTP-induced neurotoxicity in mice.; Mov. Discord, 14 612
4) Auffret et al. (2017), Apomorphine pump in advanced Parkinson’s disease: Effects on motor and nonmotor symptoms with brain metabolism correlations; J. Neurol. Sci, 372 279
5) Jenner and Katzenschlager (2016), Apomorphine – pharmacological properties and clinical trials in Parkinson’s disease; Parkinsonism. Related. Disord., 33 Suppl. 1:S13
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.